DCT

1:26-cv-01192

Mylan Pharma Inc v. Novo Nordisk Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-01192, D. Del., 09/23/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware based on Defendants' marketing and sales of pharmaceutical products, including Wegovy®, within the district, as well as Defendants' previous submission to the court's jurisdiction in related litigation.
  • Core Dispute: Plaintiff Mylan seeks a declaratory judgment that its proposed generic semaglutide drug products do not infringe, and/or that U.S. Patent No. 12,551,536, owned by Defendant Novo Nordisk A/S and listed for the drug Wegovy®, is invalid.
  • Technical Context: The dispute centers on a method-of-use patent for semaglutide, a GLP-1 receptor agonist, in the field of medical weight management, a significant and growing pharmaceutical market.
  • Key Procedural History: The action arises under the Hatch-Waxman Act. Mylan filed an Abbreviated New Drug Application (ANDA) to market generic versions of Novo Nordisk's Wegovy®. In response to Mylan’s Paragraph IV certification, Novo Nordisk listed the patent-in-suit in the FDA's Orange Book but did not initiate an infringement action within the statutory 45-day period. This procedural posture enabled Mylan to file this declaratory judgment action to establish its right to market its products upon FDA approval. The parties are also engaged in separate, ongoing litigation over a related parent patent involving the same ANDA.

Case Timeline

Date Event
2017-10-12 '536 Patent Priority Date
2022-11-30 Mylan receives ANDA Acknowledgment Letter from FDA
2026-02-17 '536 Patent Issue Date
2026-06-17 Mylan sends Paragraph IV Certification Notice
2026-09-23 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,551,536 - "Semaglutide in Medical Therapy"

  • Patent Identification: U.S. Patent No. 12,551,536, "Semaglutide in Medical Therapy", issued February 17, 2026.

The Invention Explained

  • Problem Addressed: The patent's background section notes that while medical therapies for weight management exist, such as other GLP-1 receptor agonists, "improved medical therapies... are still desired" '536 Patent, col. 1:29-31 A key challenge with this class of drugs is managing gastrointestinal side effects, particularly nausea, as dosages are increased to achieve greater efficacy '536 Patent, col. 1:26-29
  • The Patented Solution: The patent describes the "surprisingly found" discovery that administering high doses of semaglutide (e.g., 2.0-4.0 mg once weekly) results in an "unexpected beneficial ratio" between body weight reduction and the safety profile '536 Patent, col. 2:48-54 The invention is based on the finding that the increase in adverse gastrointestinal events at these high doses was "surprisingly was lower than the improvement in body weight reduction," enabling greater weight loss than previously thought possible with a manageable side-effect profile '536 Patent, col. 2:56-59
  • Technical Importance: The invention claims a method to achieve a more favorable risk-benefit profile for semaglutide in weight management, potentially allowing for greater efficacy than existing treatments while maintaining patient tolerability '536 Patent, col. 2:48-54

Key Claims at a Glance

  • The complaint primarily references independent claim 1 ('Compl. ¶31). The prayer for relief seeks a declaration of non-infringement and invalidity as to all claims of the patent ('Compl., Prayer for Relief ¶A).
  • Independent Claim 1:
    • A method for reducing body weight of a subject in need thereof,
    • comprising administering semaglutide
    • subcutaneously to the subject
    • in an amount of 2.0-10.0 mg weekly.

III. The Accused Instrumentality

Product Identification

"Mylan's Proposed ANDA Products," which are generic semaglutide prefilled single-dose pens intended for subcutaneous injection ('Compl. ¶5).

Functionality and Market Context

The products are designed to be generic equivalents to Novo Nordisk's brand-name drug, Wegovy® ('Compl. ¶¶3-5). They contain semaglutide and are intended for use in weight management ('Compl. ¶¶3-5). Mylan seeks approval to market its products in several dosages, including 2.4 mg/0.75 mL, 1.7 mg/0.75 mL, 1.0 mg/0.5 mL, 0.5 mg/0.5 mL, and 0.25 mg/0.5 mL ('Compl. ¶5). The 2.4 mg dose corresponds to the highest maintenance dose of Wegovy®, while the lower doses are typically used for dose escalation to improve tolerability ('Compl. ¶11; Compl. ¶33).

IV. Analysis of Infringement Allegations

This is a declaratory judgment action for non-infringement, so the complaint does not contain a formal infringement claim chart. The table below summarizes the basis for the justiciable controversy by mapping the elements of the representative asserted claim to the features of Mylan's products as described in the complaint.

No probative visual evidence provided in complaint.

'536 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for reducing body weight of a subject in need thereof Mylan's proposed products are generic versions of Wegovy®, a drug indicated for chronic weight management. ¶3; ¶5 col. 5:9-12
comprising administering semaglutide Mylan's Proposed ANDA Products are described as prefilled single-dose pens containing semaglutide. ¶5 col. 2:48-50
subcutaneously to the subject The Wegovy® label, for which Mylan seeks to provide a generic equivalent, specifies subcutaneous use. ¶5; ¶11; ¶31 col. 5:19-22
in an amount of 2.0-10.0 mg weekly Mylan's ANDA includes a proposed product with a 2.4 mg once-weekly dose, which falls within the claimed range. ¶5; ¶31; ¶33 col. 6:1-3

Identified Points of Contention

  • Scope Questions: A primary point of contention may be whether Mylan’s proposed products with dosages below 2.0 mg per week (e.g., 1.7 mg, 1.0 mg, 0.5 mg, 0.25 mg) fall outside the literal scope of claim 1 ('Compl. ¶5). This raises the question of whether a dose-escalation regimen, which starts at a non-infringing dose but is designed to reach a maintenance dose within the claimed 2.0-10.0 mg range, would constitute induced or contributory infringement.
  • Validity Questions: The complaint alleges that the '536 patent is invalid ('Compl. ¶6; Compl. ¶58). Given that Mylan’s 2.4 mg product appears to fall within the literal scope of claim 1, the case may focus heavily on Mylan's invalidity contentions, such as anticipation or obviousness based on prior art related to semaglutide dosing.

V. Key Claim Terms for Construction

  • The Term: "an amount of 2.0-10.0 mg weekly"
  • Context and Importance: The definition of this dosage range is central to the infringement analysis. Mylan's 2.4 mg proposed product falls directly within this range, while its other, lower-dose products fall outside it ('Compl. ¶5). The construction of this term will determine which of Mylan's products are directly implicated and will be critical for analyzing any claims of indirect infringement based on dose-escalation instructions.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent claims a "method for reducing body weight" '536 Patent, claim 1 A party could argue that any complete treatment regimen intended to achieve weight loss that culminates in a maintenance dose within the 2.0-10.0 mg weekly range practices the invention, even if initial titration doses are lower. The specification's own clinical trial examples describe dose escalation protocols, which may support the view that the "method" encompasses the entire course of treatment '536 Patent, col. 7:35-39
    • Evidence for a Narrower Interpretation: The claim language recites "administering... in an amount of 2.0-10.0 mg weekly" '536 Patent, claim 1 A party could argue this requires the specific act of administering a dose that is literally within that range. Under this view, administering a 1.7 mg dose would not be an act of infringement for that week. The patent emphasizes the "unexpected" benefits at "high dosages," which may support the argument that the claimed 2.0 mg lower bound is a critical and firm threshold, not merely part of a broader, multi-dose regimen '536 Patent, col. 2:50-59

VI. Other Allegations

  • Indirect Infringement: Mylan seeks a declaratory judgment that it would not "induce or contribute to the infringement by others" ('Compl., Prayer for Relief ¶C). The basis for a potential claim of inducement by Novo Nordisk would likely rest on allegations that Mylan's product labeling and physician instructions would direct medical professionals and patients to administer the drug in a manner that infringes claim 1—specifically, by titrating up to and maintaining a weekly dose of 2.0-10.0 mg for weight reduction.
  • Willful Infringement: Willfulness is not alleged by the plaintiff in this declaratory judgment action.

VII. Analyst’s Conclusion: Key Questions for the Case

This case appears to be a strategic move by a generic applicant to clear a patent hurdle after the patentee declined to sue. The key questions for the court will likely be:

  1. A central issue will be one of validity: Given that Mylan's 2.4 mg proposed product appears to fall squarely within the dosage range of claim 1, will Mylan be able to prove by clear and convincing evidence that the '536 patent is invalid for reasons such as obviousness or anticipation, as alleged in its complaint?
  2. A secondary issue concerns the scope of infringement: For Mylan’s products with dosages below the 2.0 mg weekly threshold, will the court find no infringement? Furthermore, how will the court analyze allegations of indirect infringement related to product labeling that instructs a dose-escalation regimen starting below 2.0 mg but intended to reach a maintenance dose within the patented range?
  3. A final question is strategic: What does Novo Nordisk's decision not to sue on the '536 patent within the statutory 45-day window, thereby ceding the choice of forum and timing to Mylan, suggest about its confidence in the patent or its broader litigation strategy against generic competition for Wegovy®?